Pages that link to "Q37453804"

The following pages link to New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family (Q37453804):

Displaying 34 items.

• Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors (Q24305041) (← links)
• Major role of human KLK14 in seminal clot liquefaction (Q24312968) (← links)
• Seminal Fluid-Mediated Inflammation in Physiology and Pathology of the Female Reproductive Tract (Q26742070) (← links)
• Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs). (Q34457491) (← links)
• Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes (Q34738849) (← links)
• Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring (Q34810177) (← links)
• Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains (Q35068692) (← links)
• Kallikreins - The melting pot of activity and function (Q36563056) (← links)
• Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC-MS/MS. (Q36900678) (← links)
• Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12 (Q36929003) (← links)
• Prognostic value and biological role of the kallikrein-related peptidases in human malignancies (Q37690308) (← links)
• Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action (Q37701517) (← links)
• Targeting kallikrein-related peptidases in prostate cancer (Q38191293) (← links)
• Predictions for the future of kallikrein-related peptidases in molecular diagnostics (Q38220044) (← links)
• Unleashing the therapeutic potential of human kallikrein-related serine proteases (Q38362486) (← links)
• Kallikrein-related peptidases (KLKs) and the hallmarks of cancer (Q38737293) (← links)
• Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies (Q38760061) (← links)
• Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate (Q39255478) (← links)
• Staphylococcus aureus Induces Increased Serine Protease Activity in Keratinocytes (Q39265145) (← links)
• Inhibitors of kallikrein-related peptidases: An overview. (Q39369735) (← links)
• The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents. (Q39558472) (← links)
• Birth-and-death of KLK3 and KLK2 in primates: evolution driven by reproductive biology (Q42691232) (← links)
• Exploitation of biological wastes for the production of value-added hydrolases by Streptomyces sp. MSWC1 isolated from municipal solid waste compost (Q43312767) (← links)
• Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma (Q43489162) (← links)
• Association between kallikrein-related peptidases (KLKs) and macroscopic indicators of semen analysis: their relation to sperm motility (Q46237329) (← links)
• Molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (KLK5 - KLK9), using Next-generation sequencing (Q47164608) (← links)
• Serine protease inhibitors to treat inflammation: a patent review (2011-2016). (Q47368493) (← links)
• Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review). (Q47554530) (← links)
• Ablation of kallikrein 7 (KLK7) in adipose tissue ameliorates metabolic consequences of high fat diet-induced obesity by counteracting adipose tissue inflammation in vivo (Q48053473) (← links)
• Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis. (Q51062025) (← links)
• A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering (Q56888917) (← links)
• Identifying Candidate Biomarkers for Pleomorphic Adenoma: A Case-Control Study (Q57168734) (← links)
• Discovery of novel transcripts of the human tissue kallikrein (KLK1) and kallikrein-related peptidase 2 (KLK2) in human cancer cells, exploiting Next-Generation Sequencing technology (Q88255485) (← links)
• Tazarotene-Induced Gene 1 (TIG1) Interacts with Serine Protease Inhibitor Kazal-Type 2 (SPINK2) to Inhibit Cellular Invasion of Testicular Carcinoma Cells (Q92313378) (← links)